## JNJ: Johnson & Johnson - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.8% below STRENGTH zone (3.0-6.0%); PEG 1.14 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-6.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($199.18)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Johnson & Johnson Stock (JNJ) News Today: FDA Approvals, Analyst Price Targets, and the 2026 Outlook (Dec. 18, 2025)**
- Source: ts2.tech | 20251218T190816 | Somewhat-Bullish | Relevance: 100%
- Johnson & Johnson (JNJ) stock saw a busy news cycle on December 18, 2025, driven by new FDA approvals for its MedTech and oncology segments, including TRUFILL n-BCA and RYBREVANT FASPRO. Despite these positive developments, the stock continues to face an overhang from ongoing talc litigation, including a recent $40 million jury verdict. While some analysts have raised price targets, the consensus upside for JNJ remains modest after its strong 2025 performance, highlighting a split between bullish and base-case valuations.

**2. J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant**
- Source: Yahoo Finance | 20251218T180805 | Bullish | Relevance: 100%
- Johnson & Johnson (JNJ) has received FDA approval for Rybrevant Faspro, a subcutaneous formulation of its NSCLC drug Rybrevant, offering improved patient convenience with a five-minute administration time. This approval allows J&J to better compete with AstraZeneca's Tagrisso and supports the company's ambitious goal of reaching $50 billion in oncology sales by the end of the decade. The decision is based on data showing its effectiveness is comparable to the intravenous version, following a previous rejection due to manufacturing concerns.

**3. Johnson & Johnson Stock (JNJ) News Today: RBC Raises Target to $240 as FDA Actions and Talc Verdict Shape the 2026 Outlook**
- Source: ts2.tech | 20251217T190813 | Somewhat-Bullish | Relevance: 100%
- RBC has raised its price target for Johnson & Johnson (JNJ) stock to $240, maintaining an Outperform rating, as the company navigates significant FDA approvals and ongoing talc litigation. JNJ shares are currently trading around $210, with investors balancing the company's defensive qualities and pipeline catalysts against the financial implications of legal challenges. The mixed sentiment reflects both JNJ's strong fundamentals and potential near-term headwinds.

**4. Johnson & Johnson Rival Medline Pulls Off $6B IPO, Topping 2025 Deal Table**
- Source: TipRanks | 20251217T110804 | Neutral | Relevance: 94%
- Medline Industries, a medical supply firm and rival to Johnson & Johnson, has successfully raised $6.3 billion in its initial public offering (IPO), becoming the largest public debut of 2025. The company surpassed its own forecasts and expectations, aided by strong investor demand and the utilization of a "greenshoe" overallotment option. This significant IPO performance suggests investor confidence in Medline's resilience to policy changes despite previous market volatility.

**5. Medtronic, J&J MedTech both get FDA nods for liquid embolic systems**
- Source: MassDevice | 20251218T152819 | Somewhat-Bullish | Relevance: 91%
- Medtronic and Johnson & Johnson MedTech have both received FDA approvals for their respective liquid embolic systems (LES) to treat symptomatic subacute and chronic Subdural Hematoma (cSDH) as an adjunct to surgery. Medtronic's Onyx LES and J&J MedTech's TruFill n-BCA LES demonstrated effectiveness in clinical trials, with Onyx showing decreased recurrence and re-operation rates and TruFill n-BCA proving superior to standard care. These approvals signify advancements in minimally invasive neurovascular treatment options.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Goldman Sachs | $240 | $213 | +13% |
| 2025-12-15 | B of A Securiti | $220 | $204 | +8% |
| 2025-12-12 | Morgan Stanley | $197 | $190 | +4% |
| 2025-12-11 | Citigroup | $232 | $215 | +8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Goldman Sachs | main | Buy |
| 2025-12-15 | B of A Securiti | main | Neutral |
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-11 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 5 ($3.81M) |
| Sells | 6 ($0.64M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.2%)
- Blackrock Inc.: 8.6% (+1.7%)
- State Street Corpora: 5.5% (-0.4%)
- JPMORGAN CHASE & CO: 4.9% (+109.0%)
- Geode Capital Manage: 2.3% (-7.2%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-6.6% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 7 raises (avg +9%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 1.14 suggests fair value with growth premium. Forward P/E 17.9x stretched relative to 6% growth. Quality metrics strong (ROE 34%, margin 27%). Balance sheet: $8.4B free cash flow. Analyst sentiment positive (7 raises, avg +9%). Insider buying signal ($3.8M), management confidence. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $497.2B |
| Beta | 0.35 |
| 52W Range | $140.68 - $215.19 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.14 |
| Forward P/E | 17.9 |
| Current P/E | 19.0 |
| YoY Growth | 6.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 5.8% to -0.8% (-6.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.8pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.20x) but short-term weakness (below SMA20). RSI neutral at 55. OFD pattern: -SUH (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.82% (CS: 39) | Neutral |
| RSI_14 | 55.4 | Neutral |
| MACD Histogram | -0.34 | Bearish |
| vs SMA20 | 1.000x | Below |
| vs SMA50 | 1.044x | Above |
| vs SMA200 | 1.197x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $206.48
- **Stop Loss:** $199.18 (3.5% risk)
- **Target:** $213.78 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 164
- **Position Value:** $33,862.72
- **Portfolio %:** 33.86%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-01-21 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.76 | $2.80 | +1.5% |
| 2025Q2 | $2.68 | $2.77 | +3.2% |
| 2025Q1 | $2.58 | $2.77 | +7.4% |
| 2024Q4 | $2.01 | $2.04 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*